No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
340 |
4. Check minimum number of eventsNone |
340 |
5. Include endpointsNone |
340 |
6. Filter based on genotype QC (FinnGen only) |
332 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E23
- Name in latin
- Diabetes insipidus
Similar endpoints
↥List of similar endpoints to
Diabetes insipidus
based on the number of shared cases.
Similar with more cases:
- Exclusions for E4_PCOS_BROAD
- Developmental endpoint to exclude non autoimmune-cases from E4_HYTHY_AI_STRICT
- Disorders of other endocrine glands
- Used for control exclusion in common control thyroid runs
- Endocrine, nutritional and metabolic diseases
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1936 | 1022 | 905 |
| Only index persons | 1614 | 884 | 730 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.03 | 0.03 | 0.03 |
| Only index persons | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | |||
| Whole population | 43.88 | 45.33 | 42.11 |
| Only index persons | 42.57 | 44.24 | 40.55 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 332 | 208 | 124 |
| Unadjusted period prevalence (%) | 0.07 | 0.07 | 0.06 |
| Median age at first event (years) | 47.96 | 47.04 | 49.49 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 340
- Matched controls
- 3400
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E23.2
ICD-10 Finland
Diabetes insipidus
+∞
307.7
311
*
H01BA02
ATC
desmopressin; nasal, systemic, sublingual
326.2
307.7
259
33
102
Kela drug reimbursment
Diabetes insipidus
+∞
261.5
216
*
H02AB09
ATC
hydrocortisone; systemic
60.3
181.4
105
25
E23.00
ICD-10 Finland
Panhypopituitarism
+∞
96.6
88
*
101
Kela drug reimbursment
Anterior pituitary hypofunction
+∞
90.8
83
*
AA4CG
NOMESCO Finland
Extensive MRI examination of sella turcica with high intensity magnet
1072.7
87.7
82
*
D35.2
ICD-10 Finland
Benign neoplasm: Pituitary gland
472.8
78.2
75
*
Z03.80
ICD-10 Finland
Observation for other suspected diseases and conditions
19.1
70.9
59
37
H03AA01
ATC
levothyroxine sodium; systemic
5.6
54.5
164
487
AAE10
NOMESCO Finland
Transsphenoidal total or partial excision of intracranial lesion
185.6
47.2
48
*
2535A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Diabetes insipidus
+∞
40.4
38
*
R35
ICD-10 Finland
Polyuria
7.6
38.9
61
95
H53.4
ICD-10 Finland
Visual field defects
14.8
38.8
36
27
G03BA03
ATC
testosterone; systemic, rectal, sublingual, transdermal
9.6
38.3
48
57
E87.1
ICD-10 Finland
Hypo-osmolality and hyponatraemia
9.2
37.7
49
61
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.1
36.0
71
140
25390
ICD-8 Finland
Diseases of pituitary gland, Diabetes insipidus
+∞
35.0
33
*
R63.1
ICD-10 Finland
Polydipsia
94.2
31.4
34
*
H01AC01
ATC
somatropin; parenteral
+∞
29.6
28
*
XCK00
NOMESCO Finland
Perimetry
6.4
29.3
53
95
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
9.2
27.5
35
42
N05AN01
ATC
lithium; oral
9.0
23.5
30
36
AA1AD
NOMESCO Finland
CT of head and brain
3.2
22.1
124
517
D35.30
ICD-10 Finland
Craniopharyngoma
+∞
21.1
20
*
301
Kela drug reimbursment
Growth hormone
+∞
21.1
20
*
N25.1
ICD-10 Finland
Nephrogenic diabetes insipidus
+∞
21.1
20
*
E87.0
ICD-10 Finland
Hyperosmolality and hypernatraemia
82.1
20.9
23
*
D44.3
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Pituitary gland
211.8
19.8
20
*
E23.05
ICD-10 Finland
Lack of TSH
+∞
18.9
18
*
E23.09
ICD-10 Finland
Pituitary insufficiency NOS
+∞
17.9
17
*
TAB00
NOMESCO Finland
Lumbar puncture
5.1
17.8
40
87
AA4BG
NOMESCO Finland
MRI examination of sella turcica with high intensity magnet
189.5
17.7
18
*
ZXC86
NOMESCO Finland
Use of endoscopic device
66.8
16.9
19
*
E23.6
ICD-10 Finland
Other disorders of pituitary gland
+∞
16.8
16
*
E23.02
ICD-10 Finland
Neurosecretory dysfunction of the growth hormone
+∞
15.7
15
*
L28
ICPC
Limited function/disability (L)
3.1
15.6
76
286
N03AX14
ATC
levetiracetam; systemic
7.2
15.0
23
34
E23.0
ICD-10 Finland
Hypopituitarism
+∞
14.7
14
*
E89.30
ICD-10 Finland
Postprocedural hypopituitarism
+∞
14.7
14
*
Z01.0
ICD-10 Finland
Examination of eyes and vision
2.8
14.6
90
385
N03AG01
ATC
valproic acid; systemic, rectal
4.4
14.5
39
98
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
3.0
13.7
72
282
TPH04
NOMESCO Finland
Cathetrisation of vein
2.6
13.0
93
427
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
3.2
12.8
57
202
N05AA02
ATC
levomepromazine; systemic
4.9
12.6
29
64
AA4CM
NOMESCO Finland
Extensive MRI examination of sella turcica with 3 Tesla magnet
+∞
12.6
12
*
E22.0
ICD-10 Finland
Acromegaly and pituitary gigantism
+∞
12.6
12
*
E23.03
ICD-10 Finland
Lack of ACTH
+∞
12.6
12
*
AA4DG
NOMESCO Finland
Very extensive MRI examination of sella turcica with high intensity magnet
+∞
12.6
12
*
WX882
NOMESCO Finland
High dependency care
12.3
12.5
22
19
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.4
12.4
49
161
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
15.1
12.4
20
14
A12BA01
ATC
potassium chloride; oral
5.4
12.4
25
49
E03.9
ICD-10 Finland
Hypothyroidism, unspecified
3.0
12.4
63
241
R42
ICD-10 Finland
Dizziness and giddiness
2.6
12.3
92
430
AAB10
NOMESCO Finland
Partial excision of intracranial lesion
16.7
12.3
19
12
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.9
12.1
66
262
9350/1-C75.2
ICD-O-3
Craniopharyngioma, NOS, of craniopharyngeal duct
+∞
11.5
11
*
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.5
11.3
42
133
R51.80
ICD-10 Finland
Headache
2.6
11.2
80
364
N05AF03
ATC
chlorprothixene; systemic
5.5
11.2
22
42
R60.0
ICD-10 Finland
Localized oedema
3.0
10.9
52
191
N05BA01
ATC
diazepam; systemic, rectal
2.7
10.9
65
270
N05AH04
ATC
quetiapine; oral
2.5
10.9
84
396
R33
ICD-10 Finland
Retention of urine
3.8
10.8
34
96
N04BC06
ATC
cabergoline; oral
62.0
10.7
12
*
N05AH03
ATC
olanzapine; systemic
3.5
10.5
38
118
E22.1
ICD-10 Finland
Hyperprolactinaemia
+∞
10.5
10
*
E23
ICD-10 Finland
Hypofunction and other disorders of pituitary gland
+∞
10.5
10
*
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.7
10.4
62
257
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.3
10.4
110
595
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
2.5
10.4
79
370
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
3.0
10.3
49
180
N05CD07
ATC
temazepam; oral
3.0
10.3
50
186
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
3.3
10.2
40
131
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
4.9
10.2
23
50
ZXC95
NOMESCO Finland
Use of surgical navigator
11.1
9.9
18
17
N91.1
ICD-10 Finland
Secondary amenorrhoea
13.9
9.8
16
12
R53
ICD-10 Finland
Malaise and fatigue
2.2
9.7
101
541
25310
ICD-8 Finland
Diseases of pituitary gland, Panhypopituitarismus
+∞
9.4
9
*
E21.0
ICD-10 Finland
Primary hyperparathyroidism
+∞
9.4
9
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
+∞
9.4
9
*
UKC02
NOMESCO Finland
Cystoscopy
2.6
9.4
58
245
G03FB08
ATC
dydrogesterone and estrogen; systemic
3.5
9.2
33
102
E23.04
ICD-10 Finland
Hypogonadotropic hypogonadism
24.8
9.0
12
5
A06AD11
ATC
lactulose; oral
2.6
8.8
56
239
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
8.8
159
1040
N06AX03
ATC
mianserin; oral
3.9
8.8
26
70
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
3.7
8.7
28
80
R50.9
ICD-10 Finland
Fever, unspecified
2.5
8.6
62
281
SPAT1226
SPAT
Implementation of occupational therapy rehabilitation plan
9.4
8.6
17
19
XCW99
NOMESCO Finland
Other investigative procedure of eye
2.8
8.6
46
180
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
7.7
8.6
19
26
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.2
8.5
23
58
WZC00
NOMESCO Finland
Treatment plan or consultation
2.0
8.4
134
835
D35.31
ICD-10 Finland
Cyst in Rathke's pocket
+∞
8.4
8
*
2542
FHL
Transasal hypophysectomy
+∞
8.4
8
*
22620
ICD-8 Finland
Benign neoplasm of endocrine glands, Pituitary gland and craniopharyngeal duct (pouch)
+∞
8.4
8
*
E23.3
ICD-10 Finland
Hypothalamic dysfunction, not elsewhere classified
+∞
8.4
8
*
E23.06
ICD-10 Finland
Empty sella
+∞
8.4
8
*
Z01.8
ICD-10 Finland
Other specified special examinations
2.2
8.2
88
473
N05BA04
ATC
oxazepam; oral
2.1
8.2
100
566
J01MA12
ATC
levofloxacin; systemic
2.3
8.1
68
330
T36
ICD-10 Finland
Poisoning by systemic antibiotics
3.9
8.1
24
65
C02AC05
ATC
moxonidine; oral
4.1
8.0
22
56
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
6.9
8.0
19
29
SPAT1255
SPAT
Intravenous administration of medicine
3.4
8.0
29
90
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
2.4
8.0
61
284
N30.0
ICD-10 Finland
Acute cystitis
2.4
7.8
61
287
A50
ICPC
General and Unspecified, Medication/prescr/renewal
4.5
7.8
19
44
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
3.8
7.7
24
67
R11
ICD-10 Finland
Nausea and vomiting
2.8
7.7
41
160
T99
ICPC
Endocr/metab/nutrit disease other
8.3
7.7
16
20
H47.2
ICD-10 Finland
Optic atrophy
25.7
7.6
10
*
XF400
NOMESCO Finland
ECG with 12 standard connections
2.4
7.5
57
264
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.3
7.4
61
293
G03DB01
ATC
dydrogesterone; oral
2.4
7.3
52
234
E23.08
ICD-10 Finland
Hypopituitarism
+∞
7.3
7
*
2273A
ICD-9 Finland
Benign neoplasm of other endocrine glands and related structures, Pituitary gland and craniopharyngeal duct (pouch)
+∞
7.3
7
*
25320
ICD-8 Finland
Diseases of pituitary gland, Chromophobe adenoma, pituitary
+∞
7.3
7
*
E23.01
ICD-10 Finland
Isolated deficiency of growth hormone
+∞
7.3
7
*
UJF32
NOMESCO Finland
Coloscopy
2.0
7.3
90
508
R56.8
ICD-10 Finland
Other and unspecified convulsions
3.5
7.3
25
75
PH2AE
NOMESCO Finland
Ultrasound examination of lower leg veins
2.6
7.2
44
184
N03AX09
ATC
lamotrigine; oral
3.3
7.2
28
91
U04
ICPC
Incontinence urine
3.6
7.1
24
71
A41.9
ICD-10 Finland
Sepsis, unspecified
4.4
7.1
18
43
G47.3
ICD-10 Finland
Sleep apnoea
2.0
7.1
88
498
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.1
7.1
85
475
G04BD04
ATC
oxybutynin; oral, transdermal
3.1
7.0
30
103
TKC20
NOMESCO Finland
Catheterisation of bladder
3.1
7.0
29
98
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
1.9
6.9
116
726
WX408
NOMESCO Finland
General anesthesy, balanced
2.0
6.9
94
548
ZYC01
NOMESCO Finland
Remote contact by phone
2.9
6.9
33
121
WX892
NOMESCO Finland
Monitored bed care
3.0
6.9
31
110
Z71.3
ICD-10 Finland
Dietary counselling and surveillance
3.5
6.7
23
69
Z2446
NOMESCO Finland
Social worker
3.0
6.6
30
107
121
Kela drug reimbursment
Severe hypofunction of sexual glands
7.1
6.6
15
22
AAF05
NOMESCO Finland
Ventriculoperitoneal shunt
10.3
6.6
12
12
KA1AE
NOMESCO Finland
Kidney ultrasound examination
5.9
6.5
17
30
R51
ICD-10 Finland
Headache
3.2
6.5
26
86
K90
ICPC
Stroke/cerebrovascular accident
7.6
6.5
14
19
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
71.1
6.4
7
*
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
2.8
6.4
33
126
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
3.4
6.4
23
71
XCK10
NOMESCO Finland
Photography of fundus of eye
2.5
6.3
40
170
J01FF01
ATC
clindamycin; systemic
1.9
6.3
97
589
A41.5
ICD-10 Finland
Sepsis due to other Gram-negative organisms
5.2
6.3
18
36
2532A
ICD-9 Finland
Disorders of the pituitary gland and its hypothalamic control, Panhypopituitarism[PANHYPOPITUITARISMUS]
+∞
6.3
6
*
E27.2
ICD-10 Finland
Addisonian crisis
+∞
6.3
6
*
N17.9
ICD-10 Finland
Acute renal failure, unspecified
4.1
6.2
17
43
J01MA02
ATC
ciprofloxacin; systemic
1.8
6.2
128
852
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.1
6.1
25
84
G04BD12
ATC
mirabegron; oral
2.4
6.1
43
193
WX105
NOMESCO Finland
Surface analgesia on skin or mucosa
2.5
6.1
41
180
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
6.2
6.1
15
25
WX402
NOMESCO Finland
General anaesthesia
2.0
6.0
76
430
C03CA01
ATC
furosemide; systemic
1.9
6.0
87
516
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.6
6.0
35
143
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
132
24
89.27
243.53
3.7
1.2
294.46
278.50
mosm/kgh2o
2.53
114
18
176
261
12.91
126.98
5.2
1.7
299.90
381.24
nmol/l
4.38
165
241
60
71
10.05
48.34
2.3
1.1
7.72
9.16
u/l
0.36
47
57
254
1264
4.99
40.09
10.2
6.5
1.22
1.21
mmol/l
0.84
209
1083
231
1151
4.14
34.35
10.3
5.9
1.22
1.21
mmol/l
0.45
215
1062
37
38
10.80
32.68
2.5
1.4
0.25
0.29
nmol/l
0.26
28
31
73
168
5.26
31.00
4.4
1.9
13.23
13.36
nmol/l
0.05
67
156
38
60
7.00
23.62
1.7
1.3
1222.04
170.27
e6/l
0.84
27
49
38
60
7.00
23.62
1.6
1.2
378.00
7.23
e6/l
0.49
26
48
105
409
3.27
20.86
3.4
3.3
0.84
0.82
mmol/l
1.07
99
387
52
125
4.73
20.62
2.1
1.3
14.84
23.54
iu/l
0.98
41
102
29
22
14.29
17.30
1.9
1.1
—
—
—
0
0
147
776
2.58
15.83
3.4
2.1
162.03
210.54
u/l
0.73
142
733
292
2162
3.48
15.59
8.6
3.8
15.02
14.65
pmol/l
1.49
279
1973
23
13
18.86
15.37
1.1
1.1
142.38
166.67
mmol/24h
0.41
23
13
219
1435
2.48
14.22
5.7
5.7
9.02
10.75
umol/l
3.76
212
1364
71
274
3.01
13.84
10.0
10.2
1.25
1.32
mmol/l
0.05
57
226
21
34
6.52
12.62
1.1
1.0
—
—
—
0
0
228
1570
2.37
12.51
8.3
4.6
6.63
6.59
mmol/l
0.10
214
1463
178
1125
2.22
11.74
3.5
2.2
77.95
76.19
nmol/l
0.38
162
1003
157
951
2.21
11.43
4.1
2.8
—
—
—
0
0
69
290
2.73
11.36
9.8
7.0
106.48
104.04
mmol/l
2.20
69
290
55
205
3.01
11.29
7.3
3.8
1.67
2.18
mmol/l
0.67
48
165
142
850
2.15
10.42
2.9
2.3
82.99
62.28
u/l
0.28
128
781
75
345
2.51
10.22
2.7
2.1
2.38
2.37
g/l
0.06
68
319
70
320
2.50
9.63
2.8
2.1
26.26
23.34
%
0.48
59
281
22
32
7.27
9.48
1.1
1.0
—
—
—
0
0
178
1193
2.03
9.36
8.9
10.7
1.10
1.20
inr
1.32
54
347
20
42
5.00
9.18
2.1
4.7
30.73
33.89
umol/l
0.30
15
36
109
623
2.10
8.74
2.1
1.9
2.79
3.11
mg/l
0.76
100
535
76
376
2.32
8.72
2.7
2.1
14.93
13.78
umol/l
0.33
71
350
13
8
16.82
8.62
2.2
1.0
—
—
—
0
0
140
881
2.00
8.60
3.7
3.2
2.33
2.35
mmol/l
0.69
128
781
120
724
2.02
8.23
3.3
2.7
1.05
0.39
e6/l
0.54
97
542
40
149
2.91
8.17
9.3
6.7
24.53
25.04
mmol/l
0.37
40
149
14
12
12.11
8.15
1.2
1.0
—
—
—
0
0
154
1019
1.93
8.04
2.0
1.9
108.42
95.92
pmol/l
1.54
75
524
269
2157
2.18
7.96
9.2
6.7
79.15
76.33
u/l
0.52
260
2019
77
398
2.21
7.90
2.3
1.8
—
—
—
0
0
15
17
9.17
7.62
1.0
1.0
—
—
—
0
0
18
30
6.27
7.18
1.1
1.0
—
—
—
0
0
27
86
3.32
7.16
1.7
1.7
—
—
—
0
0
42
174
2.61
7.01
2.0
1.4
—
—
—
0
0
11
8
14.15
6.93
2.6
1.0
2.42
5.85
umol/l
—
11
8
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
13
14
9.60
6.84
1.2
1.1
—
—
—
0
0
38
152
2.69
6.79
6.5
4.3
2.22
1.94
mmol/l
0.17
31
117
28
95
3.12
6.71
1.7
1.9
—
—
—
0
0
257
2079
1.97
6.66
5.2
3.9
11.32
10.62
mm/h
0.45
241
1922
99
595
1.94
6.66
1.6
1.5
22.15
21.00
nmol/l
0.29
83
503
88
508
1.99
6.65
1.8
1.7
464.58
440.45
pmol/l
0.40
73
443
215
1646
1.83
6.60
12.4
8.8
4.52
3.99
e9/l
1.96
201
1439
298
2575
2.27
6.01
7.6
5.3
40.10
39.44
mmol/mol
0.47
284
2415
109
700
1.82
5.86
3.4
3.1
950.66
935.54
ng/l
0.02
93
585
300
2607
2.28
5.83
8.3
4.5
1.53
1.86
mu/l
4.03
271
2391
188
1421
1.72
5.66
4.8
3.4
0.00
0.01
estimate
0.50
41
247
184
1396
1.69
5.35
5.0
3.3
0.00
0.00
estimate
-0.00
41
267
57
303
2.06
5.34
2.1
2.4
4.90
7.67
umol/l
1.15
44
258
185
1407
1.69
5.32
5.9
4.5
0.00
0.00
estimate
-0.00
40
253
133
930
1.71
5.21
3.7
2.9
37.30
30.48
u/l
0.52
127
892
98
629
1.78
5.20
2.7
2.2
—
—
—
0
0
8
6
13.61
5.10
1.3
1.0
—
—
—
0
0
164
1223
1.66
4.98
3.5
2.5
119.97
100.91
ug/l
0.45
156
1128
47
239
2.12
4.94
3.8
3.0
—
—
—
0
0
31
132
2.48
4.90
2.0
1.6
—
—
—
0
0
139
1002
1.66
4.76
4.7
3.3
35.25
37.63
ng/l
0.07
104
640
14
30
4.82
4.73
1.6
1.2
—
—
nmol/l
—
0
0
176
1348
1.63
4.72
8.6
5.5
27.56
28.39
%
0.41
169
1267
15
43
3.60
4.67
2.3
2.5
17.48
16.35
%
—
10
20
174
1332
1.63
4.66
8.2
5.4
57.07
56.80
%
0.10
167
1251
7
5
14.25
4.59
1.1
1.0
—
—
—
0
0
305
2729
2.14
4.51
5.9
4.3
5.93
5.89
mmol/l
0.21
289
2517
32
145
2.33
4.44
1.5
1.3
—
—
—
0
0
10
16
6.40
4.32
1.0
1.1
1.72
1.02
u/l
—
5
10
7
6
11.87
4.29
1.3
1.0
—
—
—
0
0
7
6
11.87
4.29
1.3
1.0
—
—
—
0
0
9
13
7.08
4.19
1.0
1.0
—
—
—
0
0
69
424
1.79
4.16
3.0
2.5
0.69
0.92
e6/l
0.42
42
232
91
608
1.68
4.08
1.9
1.7
1.30
1.06
mg/l
0.41
66
463
114
810
1.61
4.00
3.3
2.9
6.65
7.88
mmol/l
1.88
103
695
20
76
2.73
3.97
1.4
1.4
0.12
0.06
iu/ml
—
7
12
297
2660
1.92
3.96
21.2
11.2
83.21
84.38
ml/min/173m2
0.36
270
2151
13
32
4.18
3.94
1.1
1.1
—
—
—
0
0
97
666
1.64
3.89
1.4
1.3
2.99
1.58
u/ml
0.41
24
184
71
451
1.73
3.81
1.9
1.6
1229.42
1175.13
nmol/l
0.20
57
341
49
278
1.89
3.80
2.3
1.6
—
—
—
0
0
11
24
4.70
3.77
1.5
1.6
—
—
—
0
0
6
5
12.18
3.77
1.2
1.0
—
—
—
0
0
144
1094
1.55
3.74
5.3
3.4
—
—
—
0
0
310
2834
2.06
3.63
23.2
12.1
19.65
21.90
mg/l
0.78
264
2202
105
747
1.59
3.61
6.3
3.7
0.00
0.00
estimate
0.50
40
252
107
766
1.58
3.58
4.5
3.7
5.30
10.26
mg/mmol
1.39
71
476
6
6
10.15
3.51
1.0
1.3
—
—
—
0
0
33
169
2.06
3.43
2.3
2.9
85.39
145.52
ng/l
1.14
28
151
8
14
5.82
3.36
1.6
3.2
586.25
840.07
u/ml
—
8
14
24
109
2.29
3.34
1.4
1.4
0.76
1.31
u/ml
—
8
8
63
402
1.70
3.31
3.4
2.6
3.28
2.76
e6/l
0.13
33
214
6
7
8.70
3.27
2.0
1.9
13.93
19.89
umol/l
—
6
7
14
49
2.94
3.23
5.1
2.1
4.93
5.03
kpa
0.21
14
49
227
1938
1.52
3.20
4.4
2.9
42.96
45.17
u/l
0.25
214
1826
7
11
6.47
3.20
1.9
1.2
117.43
63.91
nmol/24h
—
7
11
17
68
2.58
3.09
4.3
2.5
—
—
—
0
0
11
31
3.63
3.02
1.4
1.6
—
—
—
0
0
11
31
3.63
3.02
1.4
1.6
—
—
—
0
0
70
475
1.60
2.89
3.9
3.4
400.29
216.36
ng/l
0.46
49
346
17
71
2.47
2.85
1.5
1.1
—
—
—
0
0
46
282
1.73
2.79
2.5
1.7
—
—
—
0
0
12
43
2.86
2.67
1.3
1.7
—
—
—
0
0
12
43
2.86
2.67
1.3
1.7
—
—
—
0
0
156
1271
1.42
2.59
3.1
2.4
—
—
—
0
0
11
36
3.12
2.59
1.7
1.3
—
—
—
0
0
10
31
3.29
2.54
3.4
6.0
—
4958.00
—
0
5
9
26
3.53
2.50
1.3
1.9
—
—
—
0
0
6
12
5.07
2.41
1.2
1.3
—
—
—
0
0
6
12
5.07
2.41
1.2
1.1
—
—
—
0
0
21
105
2.07
2.36
1.5
2.3
—
—
—
0
0
9
28
3.27
2.32
1.4
1.9
—
—
—
0
0
13
282
0.44
2.31
1.5
1.7
—
—
—
0
0
11
41
2.74
2.23
1.1
1.1
—
—
—
0
0
8
25
3.25
2.10
1.1
1.2
—
—
—
0
0
8
25
3.25
2.10
1.1
1.2
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
56
2.37
2.07
2.2
3.1
0.42
0.31
u/ml
—
7
29
6
15
4.05
2.04
1.0
1.2
—
1.11
—
0
6
8
26
3.13
2.02
1.1
1.2
—
—
—
0
0
8
26
3.13
2.02
1.1
1.2
—
—
—
0
0
8
26
3.13
2.02
1.1
1.2
—
—
—
0
0
16
77
2.13
2.00
1.3
1.1
—
—
—
0
0
49
334
1.55
1.99
4.5
4.1
34.00
31.24
%
0.71
40
225
14
64
2.24
1.97
2.4
2.3
45.71
96.04
ug/min
—
7
37
8
27
3.01
1.95
1.6
1.3
—
—
—
0
0
8
27
3.01
1.95
13.1
13.9
602.13
857.00
nmol/l
—
8
27
8
27
3.01
1.95
19.8
19.8
1218.75
1588.85
nmol/l
—
8
27
16
79
2.08
1.88
1.7
1.3
257.82
294.03
ug/g
0.34
11
44
10
40
2.54
1.68
1.0
1.1
46.60
12.14
iu/ml
—
5
7
13
62
2.14
1.67
1.3
1.6
—
—
—
0
0
5
14
3.61
1.62
1.0
1.0
—
—
—
0
0
18
99
1.86
1.60
1.4
1.6
—
—
—
0
0
7
26
2.73
1.59
1.4
1.3
2.13
1.35
promille
—
7
21
86
684
1.34
1.53
2.6
2.6
357.44
6791.12
umol/l
3.15
72
602
5
15
3.37
1.53
2.0
1.7
58.40
70.33
umol/l
—
5
15
286
2692
1.39
1.43
4.7
3.8
1.40
1.30
mmol/l
1.48
267
2490
86
693
1.32
1.40
4.8
4.4
2.88
2.20
ug/l
0.26
77
622
12
60
2.04
1.39
1.3
1.6
—
—
—
0
0
214
1939
1.28
1.39
3.4
3.2
—
—
—
0
0
6
23
2.64
1.37
1.5
2.0
—
—
—
0
0
10
47
2.16
1.35
1.1
1.3
—
—
—
0
0
10
47
2.16
1.35
1.1
1.3
—
—
—
0
0
26
169
1.58
1.33
1.3
1.2
64.02
347.74
u/ml
1.26
26
153
80
644
1.32
1.31
6.0
3.4
1.01
1.02
kg/l
1.90
12
87
5
18
2.80
1.29
1.4
1.8
8.92
11.66
umol/l
—
5
18
5
18
2.80
1.29
1.2
1.4
—
—
—
0
0
93
768
1.29
1.26
1.6
1.7
1.49
1.42
mmol/l
0.35
81
660
13
70
1.89
1.25
1.5
1.4
—
—
—
0
0
5
19
2.65
1.22
1.0
1.0
36.60
38.03
ng/l
—
5
11
5
19
2.65
1.22
1.0
1.0
191.40
262.27
ng/l
—
5
11
8
38
2.13
1.19
1.3
1.6
—
—
—
0
0
6
26
2.33
1.19
1.2
1.4
—
—
—
0
0
48
363
1.38
1.19
2.1
1.9
1.48
1.48
%
0.01
41
325
13
73
1.81
1.12
2.0
1.7
—
—
—
0
0
29
202
1.48
1.12
2.9
2.5
3.67
5.39
ug/l
1.03
23
180
9
46
1.98
1.04
3.7
2.9
61.56
55.54
%
—
9
46
5
22
2.29
1.03
1.8
1.1
—
—
—
0
0
5
22
2.29
1.03
1.4
1.7
32.03
16.99
ug/l
—
5
22
292
2796
1.31
0.97
5.1
4.3
4.64
4.75
mmol/l
1.23
275
2615
11
62
1.80
0.95
2.5
1.5
—
—
—
0
0
29
210
1.42
0.94
2.2
2.7
62.64
73.39
ml/min/173m2
0.63
13
88
313
3033
1.40
0.91
14.6
9.4
27.01
26.62
u/l
0.17
308
2935
63
519
1.26
0.88
1.5
1.3
18.09
33.91
iu/ml
1.72
23
164
11
64
1.74
0.87
1.4
1.3
—
—
—
0
0
8
44
1.84
0.86
1.4
1.6
—
—
—
0
0
290
2788
1.27
0.83
5.2
4.2
1.42
1.48
mmol/l
1.74
271
2592
6
32
1.89
0.82
1.0
1.7
—
—
—
0
0
28
371
0.73
0.82
1.7
2.0
—
—
—
0
0
27
199
1.39
0.81
1.1
1.2
89.73
150.97
iu/ml
—
9
87
25
335
0.73
0.79
1.8
1.9
—
—
—
0
0
39
487
0.78
0.76
1.5
1.4
—
—
—
0
0
13
85
1.55
0.70
1.0
1.1
—
15.79
—
0
12
7
120
0.57
0.69
1.1
1.5
—
—
—
0
0
294
2848
1.24
0.65
5.7
4.7
2.77
2.84
mmol/l
0.76
276
2642
21
156
1.37
0.62
1.0
1.0
—
—
—
0
0
8
51
1.58
0.61
1.3
1.3
—
—
—
0
0
10
64
1.58
0.59
1.3
1.3
—
—
—
0
0
39
320
1.25
0.59
10.3
6.2
—
—
—
0
0
8
53
1.52
0.59
1.1
1.4
—
99.80
—
0
10
8
54
1.49
0.57
1.1
1.4
—
—
—
0
0
6
37
1.63
0.56
11.2
2.2
12.95
13.20
%
—
6
37
13
93
1.41
0.49
1.0
1.4
151.89
266.80
miu/ml
—
7
49
13
94
1.40
0.46
1.9
1.9
—
—
—
0
0
7
51
1.38
0.44
1.4
1.6
—
—
—
0
0
12
87
1.39
0.43
1.9
1.3
—
—
—
0
0
0
17
0.00
0.41
0.0
1.4
—
—
—
0
0
0
17
0.00
0.41
0.0
1.6
—
—
—
0
0
0
17
0.00
0.41
0.0
4.1
—
—
—
0
0
5
34
1.48
0.40
1.0
1.5
—
—
—
0
0
5
34
1.48
0.40
1.0
1.5
—
—
—
0
0
5
34
1.48
0.40
1.0
1.5
—
—
—
0
0
5
34
1.48
0.40
1.0
1.5
—
—
—
0
0
5
35
1.43
0.39
1.0
1.5
—
—
—
0
0
5
35
1.43
0.39
1.0
1.5
—
—
—
0
0
5
35
1.43
0.39
1.2
1.4
—
—
—
0
0
5
35
1.43
0.39
1.4
2.7
105.80
106.46
mmol/l
—
5
35
6
43
1.40
0.35
1.2
1.7
—
—
—
0
0
56
507
1.13
0.31
1.5
1.3
3.88
11.28
u/ml
1.44
25
208
12
93
1.30
0.30
1.3
1.1
—
—
—
0
0
12
95
1.27
0.26
1.3
1.1
—
—
—
0
0
20
171
1.18
0.24
1.3
1.3
—
—
—
0
0
5
41
1.22
0.22
1.0
1.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.0
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
—
—
0
0
37
404
0.91
0.19
3.5
2.7
1.14
0.76
ug/l
0.34
30
248
320
3174
1.14
0.17
37.3
18.1
40.21
40.57
%
0.55
301
2998
320
3179
1.11
0.13
37.3
18.1
134.52
136.54
g/l
1.91
320
3138
11
124
0.88
0.09
1.5
1.9
—
—
—
0
0
6
57
1.05
0.08
1.3
1.8
—
—
—
0
0
15
138
1.09
0.06
3.5
2.5
0.35
0.11
e6/l
0.52
15
133
20
187
1.07
0.06
1.5
1.9
—
—
—
0
0
54
550
0.98
0.02
4.0
4.1
23.20
21.22
%
0.37
18
244
57
572
1.00
0.00
1.5
1.6
—
—
—
0
0
28
283
0.99
0.00
3.1
4.0
3.52
46.05
ug/l
0.89
22
235
10
105
0.95
0.00
1.3
1.4
—
—
—
0
0
15
154
0.97
0.00
1.5
1.8
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.8
—
36.20
—
0
5
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
9
99
0.91
-0.00
1.2
1.4
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_DIABINSIPIDUS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_DIABINSIPIDUS | 3.239 [2.46, 4.27] | < 0.001 |
| Birth year | 1.001 [0.99, 1.01] | 0.864 |
During the follow-up period (1.1.1998 — 31.12.2019), 127 out of 716 females with E4_DIABINSIPIDUS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_DIABINSIPIDUS | 2.412 [1.78, 3.27] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.015 |
During the follow-up period (1.1.1998 — 31.12.2019), 120 out of 595 males with E4_DIABINSIPIDUS died.
Mortality risk
Mortality risk for people of age
years, who have E4_DIABINSIPIDUS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.39% | 0.489% |
| 5 | 2.107% | 3.104% |
| 10 | 5.629% | 7.422% |
| 15 | 10.58% | 13.857% |
| 20 | 18.654% | 22.663% |
Relationships between endpoints
↥Index endpoint: E4_DIABINSIPIDUS – Diabetes insipidus
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data